Dr Doug Wilson to step down from AFT Board

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com






22 July 2022
Dr Doug Wilson to step down from AFT Board

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces that Dr Doug Wilson will
step down from its Board of Directors at the conclusion of the company’s Annual
Meeting of Shareholders on 5 August 2022.
Dr Wilson joined the AFT Board in 2012 following a distinguished and diverse career in
academia and business and with deep experience spanning pharmaceutical
research, development and commercialisation.
AFT Pharmaceuticals Chair David Flacks said: “Doug’s experience and expertise have
brought significant value to the Board and the AFT business. The combination of his
healthcare and commercial experience has been present during a number of
significant milestones including our NZX and ASX listings, product negotiations and
meetings with regulators around the globe. He has also brought to the board table a
world view and a genuine and abiding care for people.”
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “Doug has advised
AFT since 2008 and with his huge experience in drug development and regulatory
issues on a global level, his contribution has been invaluable. Doug is a great teacher
- we have soaked up his wisdom and are in a good place to continue our existing and
new R&D programmes. We certainly are grateful for all of Doug’s help and thank him
sincerely.”
Dr Doug Wilson – Career overview
Dr Doug Wilson joined the AFT Board in 2012 after a diverse and distinguished career.
His first job in medicine was as a nurse at Auckland Hospital during a student vacation.
Upon graduating from Otago University medical school, he undertook postgraduate
training in medicine, blood and kidney diseases and research. After moving to the UK
he gained a PhD training in haematology and immunology.
He returned to New Zealand and was appointed an associate professor at Auckland
Medical School, and this was followed by other academic roles including visiting
professor at the King Saud University in Riyadh, Saudi Arabia.
At the age of 50 he opted for a new career in business, joining the German
pharmaceutical company Boehringer Ingelheim, first as its New Zealand Medical

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

Director and ending his tenure as the company’s worldwide head of Medical
Research and Regulatory Affairs.
During this time, he led teams that developed and commercialised new drugs for
hypertension, HIV, chronic lung diseases, strokes, heart attacks, prostatic disease
among many others.
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Coran Lill
Managing Director The Project
AFT Pharmaceuticals Tel: +64 27 342 3836
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over the counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded, and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and to out-license / distribute our products to local licensees and distributors
to over 125 countries around the world. For more information about the company, visit
our website: www.aftpharm.com.